Fibrobiologics Inc
FBLG0.259USD
-0.002-0.92%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
12.48MMarket Cap
LossP/E TTM
More Details of Fibrobiologics Inc Company
FibroBiologics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with significant unmet medical needs, including wound healing, multiple sclerosis, degenerative disc disease, psoriasis and certain cancers, and potential human longevity applications including thymic involution reversal. Its product candidates include CybroCell, CYMS101 and CYWC628. CybroCell is an allogeneic fibroblast cell-based therapy for degenerative disc disease. This technology is being designed as an alternative method for repairing the cartilage of the intervertebral disc (or any other articular cartilage). It is developing CYMS101 as an allogeneic fibroblast cell-based therapy to treat multiple sclerosis (MS) and has completed the Phase I study. It is developing CYWC628 as an allogeneic fibroblast cell-based therapy for wound healing. Its CYPS317 is used for the treatment of Psoriasis.
Fibrobiologics Inc Info
Ticker SymbolFBLG
Company nameFibrobiologics Inc
IPO dateJan 31, 2024
CEOO'Heeron (Pete)
Number of employees13
Security typeOrdinary Share
Fiscal year-endJan 31
Address455 E. Medical Center Blvd
CityHOUSTON
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code77598
Phone12816715150
Websitehttps://fibrobiologics.com/
Ticker SymbolFBLG
IPO dateJan 31, 2024
CEOO'Heeron (Pete)
Company Executives of Fibrobiologics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Hamid Khoja, Ph.D.
Dr. Hamid Khoja, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
31.25K
+177.78%
Dr. Victoria Niklas, M.D.
Dr. Victoria Niklas, M.D.
Independent Director
Independent Director
7.50K
--
Mr. Robert E. Hoffman, CPA
Mr. Robert E. Hoffman, CPA
Director
Director
7.50K
--
Mr. Nic Johnson
Mr. Nic Johnson
IR Contact Officer
IR Contact Officer
--
--
Mr. Ruben Garcia
Mr. Ruben Garcia
General Counsel
General Counsel
--
--
Mr. Pete O'Heeron
Mr. Pete O'Heeron
Chairman of the Board, Chief Executive Officer, Founder
Chairman of the Board, Chief Executive Officer, Founder
--
--
Mr. Richard Cilento, Jr.
Mr. Richard Cilento, Jr.
Independent Director
Independent Director
--
--
Ms. Stacy Coen
Ms. Stacy Coen
Independent Director
Independent Director
--
--
Mr. Matthew Link
Mr. Matthew Link
Independent Director
Independent Director
--
--
Mr. Jason D. Davis
Mr. Jason D. Davis
Chief Financial Officer
Chief Financial Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Hamid Khoja, Ph.D.
Dr. Hamid Khoja, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
31.25K
+177.78%
Dr. Victoria Niklas, M.D.
Dr. Victoria Niklas, M.D.
Independent Director
Independent Director
7.50K
--
Mr. Robert E. Hoffman, CPA
Mr. Robert E. Hoffman, CPA
Director
Director
7.50K
--
Mr. Nic Johnson
Mr. Nic Johnson
IR Contact Officer
IR Contact Officer
--
--
Mr. Ruben Garcia
Mr. Ruben Garcia
General Counsel
General Counsel
--
--
Mr. Pete O'Heeron
Mr. Pete O'Heeron
Chairman of the Board, Chief Executive Officer, Founder
Chairman of the Board, Chief Executive Officer, Founder
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Dec 14
Updated: Sun, Dec 14
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
O'Heeron (Peter)
8.88%
Golden Knight Inc LP
8.53%
The Vanguard Group, Inc.
1.85%
Yorkville Advisors Global, LP.
0.77%
Millennium Management LLC
0.67%
Other
79.30%
Shareholders
Shareholders
Proportion
O'Heeron (Peter)
8.88%
Golden Knight Inc LP
8.53%
The Vanguard Group, Inc.
1.85%
Yorkville Advisors Global, LP.
0.77%
Millennium Management LLC
0.67%
Other
79.30%
Shareholder Types
Shareholders
Proportion
Individual Investor
9.32%
Corporation
8.53%
Investment Advisor
4.70%
Hedge Fund
1.71%
Investment Advisor/Hedge Fund
1.45%
Research Firm
0.25%
Family Office
0.01%
Other
74.01%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
125
5.16M
16.27%
--
2025Q3
125
5.16M
16.27%
+26.14K
2025Q2
124
5.13M
16.68%
-1.32M
2025Q1
115
6.45M
16.82%
+104.96K
2024Q4
107
5.96M
16.68%
+467.89K
2024Q3
99
5.49M
10.74%
+2.00M
2024Q2
74
3.47M
1.58%
+2.95M
2024Q1
20
483.30K
0.00%
+483.30K
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
O'Heeron (Peter)
5.91M
14.1%
--
--
Apr 21, 2025
Golden Knight Inc LP
2.13M
5.1%
+9.85K
+0.46%
Apr 21, 2025
The Vanguard Group, Inc.
1.23M
2.95%
-186.64K
-13.14%
Jun 30, 2025
Millennium Management LLC
480.64K
1.15%
+480.64K
--
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
715.58K
1.71%
-916.88K
-56.17%
Jun 30, 2025
Cascade Financial Partners, LLC
290.58K
0.69%
+30.50K
+11.73%
Jun 30, 2025
Geode Capital Management, L.L.C.
288.95K
0.69%
-325.69K
-52.99%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Russell 2000 Growth ETF
0%
ProShares Hedge Replication ETF
0%
Global X Russell 2000 ETF
0%
ProShares UltraPro Russell2000
0%
Proshares Ultra Russell 2000
0%
Texas Capital Texas Small Cap Equity Index ETF
0%
iShares Russell 2000 ETF
0%
iShares Micro-Cap ETF
0%
iShares Russell 2000 Growth ETF
Proportion0%
ProShares Hedge Replication ETF
Proportion0%
Global X Russell 2000 ETF
Proportion0%
ProShares UltraPro Russell2000
Proportion0%
Proshares Ultra Russell 2000
Proportion0%
Texas Capital Texas Small Cap Equity Index ETF
Proportion0%
iShares Russell 2000 ETF
Proportion0%
iShares Micro-Cap ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Fibrobiologics Inc?
The top five shareholders of Fibrobiologics Inc are:
O'Heeron (Peter) holds 5.91M shares, accounting for 14.10% of the total shares.
Golden Knight Inc LP holds 2.13M shares, accounting for 5.10% of the total shares.
The Vanguard Group, Inc. holds 1.23M shares, accounting for 2.95% of the total shares.
Millennium Management LLC holds 480.64K shares, accounting for 1.15% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 715.58K shares, accounting for 1.71% of the total shares.
O'Heeron (Peter) holds 5.91M shares, accounting for 14.10% of the total shares.
Golden Knight Inc LP holds 2.13M shares, accounting for 5.10% of the total shares.
The Vanguard Group, Inc. holds 1.23M shares, accounting for 2.95% of the total shares.
Millennium Management LLC holds 480.64K shares, accounting for 1.15% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 715.58K shares, accounting for 1.71% of the total shares.
What are the top three shareholder types of Fibrobiologics Inc?
The top three shareholder types of Fibrobiologics Inc are:
O'Heeron (Peter)
Golden Knight Inc LP
The Vanguard Group, Inc.
O'Heeron (Peter)
Golden Knight Inc LP
The Vanguard Group, Inc.
How many institutions hold shares of Fibrobiologics Inc (FBLG)?
As of 2025Q4, 125 institutions hold shares of Fibrobiologics Inc, with a combined market value of approximately 5.16M, accounting for 16.27% of the total shares. Compared to 2025Q3, institutional shareholding has increased by --.
What is the biggest source of revenue for Fibrobiologics Inc?
In --, the -- business generated the highest revenue for Fibrobiologics Inc, amounting to -- and accounting for --% of total revenue.
